Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the pricing of its underwritten public offering of 10,227,273 of its common shares at a price to the public of $22.00 per share. In addition, Biohaven has granted the underwriters a 30-day option to purchase up to an additional 1,534,090 common shares at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering are expected to be approximately $225 million before deducting underwriting discounts and commissions and offering expenses payable by Biohaven. The offering is expected to close on October 5, 2023, subject to satisfaction of customary closing conditions. Biohaven intends to use the net proceeds received from the offering for general corporate purposes.
J.P. Morgan, TD Cowen, Leerink Partners, and Piper Sandler are acting as the joint lead book-running managers of the offering, William Blair is acting as a book-runner of the offering and BTIG is acting as lead manager of the offering.
